Database study of adverse events in atezolizumab combination with carboplatin plus etoposide in patients with previously untreated extensive disease small cell lung cancer

Database study of adverse events in atezolizumab combination with carboplatin plus etoposide in patients with previously untreated extensive disease small cell lung cancer - Database study of adverse events in atezolizumab combination with carboplatin plus etoposide in patients with previously untreated extensive disease small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041508

Enrollment

400

Registered

2020-08-21

Start date

2020-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with small cell lung cancer

Exclusion criteria

Exclusion criteria: Patients who have been diagnosed with malignant tumors other than small cell lung cancer and have undergone chemotherapy for small cell lung cancer

Design outcomes

Primary

Measure	Time frame
Incidence, rates, severity and time to onset of adverse events, and treatment for adverse events	—

Countries

Japan

Contacts

Public ContactCHUGAI PHARMACEUTICAL CO., LTD.

Medical Affairs Div. Medical Science Dept.

cma-clinicaltrial@chugai-pharm.co.jp0332730866

Outcome results